Literature DB >> 8651263

Mental status of females with an FMR1 gene full mutation.

B B de Vries1, A M Wiegers, A P Smits, S Mohkamsing, H J Duivenvoorden, J P Fryns, L M Curfs, D J Halley, B A Oostra, A M van den Ouweland, M F Niermeijer.   

Abstract

The cloning of the FMR1 gene enables molecular diagnosis in patients and in carriers (male and female) of this X-linked mental retardation disorder. Unlike most X-linked disorders, a considerable proportion of the female carriers of a full mutation of the FMR1 gene is affected. In this study, the intelligence quotients (IQs) were ascertained by the Wechsler Adult Intelligence Scale in 33 adult females with a full mutation, with 28 first-degree adult female relatives (mainly sisters) without a full mutation as controls. Seventy-one percent of the females with a full mutation had IQ scores below 85. In paired analysis, no significant correlation could be detected between the IQs of the females with a full mutation and those of their first-degree female relatives, reflecting a dominant effect of the FMR1 gene full mutation in the mental development of females. Considering females with a full mutation only, we observed a significant relation between the proportion of normal FMR1 alleles on the active X chromosome and IQ. We present a model to explain this relationship.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8651263      PMCID: PMC1914633     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  34 in total

1.  Fragile sites on human chromosomes: demonstration of their dependence on the type of tissue culture medium.

Authors:  G R Sutherland
Journal:  Science       Date:  1977-07-15       Impact factor: 47.728

Review 2.  Organization of abilities and the development of intelligence.

Authors:  J L Horn
Journal:  Psychol Rev       Date:  1968-05       Impact factor: 8.934

3.  Primordial cell pool size and lineage relationships of five human cell types.

Authors:  P J Fialkow
Journal:  Ann Hum Genet       Date:  1973-07       Impact factor: 1.670

4.  X chromosome inactivation mosaicism in the mouse.

Authors:  M N Nesbit
Journal:  Dev Biol       Date:  1971-10       Impact factor: 3.582

5.  A marker X chromosome.

Authors:  H A Lubs
Journal:  Am J Hum Genet       Date:  1969-05       Impact factor: 11.025

Review 6.  The X inactivation centre and X chromosome imprinting.

Authors:  M F Lyon
Journal:  Eur J Hum Genet       Date:  1994       Impact factor: 4.246

7.  Modeling methylation and IQ scores in fragile X females and mosaic males.

Authors:  K Kolehmainen; Y Karant
Journal:  Am J Med Genet       Date:  1994-07-15

8.  Molecular-neurobehavioral associations in females with the fragile X full mutation.

Authors:  M T Abrams; A L Reiss; L S Freund; T L Baumgardner; G A Chase; M B Denckla
Journal:  Am J Med Genet       Date:  1994-07-15

9.  A multicenter study on genotype-phenotype correlations in the fragile X syndrome, using direct diagnosis with probe StB12.3: the first 2,253 cases.

Authors:  F Rousseau; D Heitz; J Tarleton; J MacPherson; H Malmgren; N Dahl; A Barnicoat; C Mathew; E Mornet; I Tejada
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

10.  Contribution of the FMR1 gene mutation to human intellectual dysfunction.

Authors:  A L Reiss; L S Freund; T L Baumgardner; M T Abrams; M B Denckla
Journal:  Nat Genet       Date:  1995-11       Impact factor: 38.330

View more
  60 in total

Review 1.  Genetic effects on human cognition: lessons from the study of mental retardation syndromes.

Authors:  P Nokelainen; J Flint
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-03       Impact factor: 10.154

2.  Evidence that mutations in the X-linked DDP gene cause incompletely penetrant and variable skewed X inactivation.

Authors:  R M Plenge; L Tranebjaerg; P K Jensen; C Schwartz; H F Willard
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

Review 3.  Fragile X: leading the way for targeted treatments in autism.

Authors:  Lulu W Wang; Elizabeth Berry-Kravis; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 4.  X chromosome inactivation in clinical practice.

Authors:  Karen Helene Orstavik
Journal:  Hum Genet       Date:  2009-04-25       Impact factor: 4.132

5.  The fragile X prevalence paradox.

Authors:  Paul J Hagerman
Journal:  J Med Genet       Date:  2008-04-15       Impact factor: 6.318

6.  Molecular Characterization of FMR1 Gene by TP-PCR in Women of Reproductive Age and Women with Premature Ovarian Insufficiency.

Authors:  Deepika Delsa Dean; Sarita Agarwal; Deepa Kapoor; Kuldeep Singh; Chandra Vati
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

Review 7.  Variable FMR1 gene methylation of large expansions leads to variable phenotype in three males from one fragile X family.

Authors:  B B de Vries; C C Jansen; A A Duits; C Verheij; R Willemsen; J O van Hemel; A M van den Ouweland; M F Niermeijer; B A Oostra; D J Halley
Journal:  J Med Genet       Date:  1996-12       Impact factor: 6.318

Review 8.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Authors:  Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

9.  Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel.

Authors:  H Toledano-Alhadef; L Basel-Vanagaite; N Magal; B Davidov; S Ehrlich; V Drasinover; E Taub; G J Halpern; N Ginott; M Shohat
Journal:  Am J Hum Genet       Date:  2001-07-06       Impact factor: 11.025

Review 10.  Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.

Authors:  John A Tsiouris; W Ted Brown
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.